DeepScribe’s Post

💡 Advocate for updated wound care terminology and harmonization of nomenclature 💡 Establish consensus around standards of care 💡 Identify endpoints beyond complete wound healing 💡 Update clinical trial guidance document 💡 Vet and promote adoption of updated clinical trial guidance with government and commercial payers 💡 Continue advocacy for evidence-based high-quality care and patient access to technologies and services   These are just some of the solutions discussed at the Alliance of Wound Care Stakeholders’ Wound Care Evidence Summit™  where the key question of "what type and quantity of clinical evidence is required by payers in formulating positive coverage policies for products and procedures?" was collaboratively addressed. Dive deeper into challenges and solutions in “Better Wound Care Begins With Better Evidence: Outcomes of the Wound Care Evidence Summit”, recently published in Advances in Wound Care. https://lnkd.in/eNWSRmF2 #healthadvocacy #payercollaboration #woundhealing #healthinnovation #clinicalevidence #healthcarecoverage Dr Marissa Carter, Winifred Hayes, Marcia Nusgart, Mary Ann Liebert, Inc.  

Integrating payers earlier in clinical trials can enhance diversity and accessibility, ensuring a more representative patient population and broader awareness of available trials. Moving forward, this could enable more equitable healthcare outcomes, therefore reducing disparities and improving the overall quality of patient care. #Healthcare #HealthEquity #ClinicalTrials

In the evolving healthcare landscape, oncologists are adapting to digital advancements like virtual care. Jennifer B. from CLA highlights the potential for e-visit billing, a practice that reimburses oncologists’ time and aligns with patient communication trends. Dive into our insights to understand how e-visits can contribute to your practice’s revenue. https://hubs.li/Q02CVp7v0

Patients are increasingly vocal about their desire for improved access to clinical trials and are calling for better ways to learn about available trials and seeking more support to participate in them. Industry has a crucial role to play in raising public awareness and tailoring communication about the benefits of clinical trials to the communities that will benefit the most from them. Read our full article to see Baringa's insights and recommendations for scaling patient engagement across R&D. https://lnkd.in/enpiZPnK

Patient retention is the strategy & tactics designed to keep participants enrolled in clinical trials, reducing the chance of them discontinuing. It is measured by the ability of healthcare providers to keep patients engaged in their care and coming back for future appointments. Read more: https://bit.ly/3WRCZBJ #ClinicalTrials #ClinicalResearch #PatientRetention

👉 𝗠𝗘𝗗𝗞𝗔𝗣 𝗜𝗻𝘃𝗲𝘀𝘁𝗼𝗿𝘀 𝗣𝗶𝘁𝗰𝗵 𝗘𝘃𝗲𝗻𝘁: 𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗼𝗻 𝗟𝗶𝘃 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 👈 𝗗𝗲𝗹𝗶𝗿𝗶𝘂𝗺 𝗶𝘀 𝗮 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲 𝗶𝗻 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹𝘀, affecting 25% of patients over 65 and costing the European healthcare system €180 billion annually. 𝗟𝗶𝘃 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲e is revolutionizing how hospitals 𝘁𝗮𝗰𝗸𝗹𝗲 𝘁𝗵𝗶𝘀 𝗶𝘀𝘀𝘂𝗲 𝘄𝗶𝘁𝗵 𝗶𝘁𝘀 𝗔𝗜-𝗽𝗼𝘄𝗲𝗿𝗲𝗱 𝘀𝗼𝗳𝘁𝘄𝗮𝗿𝗲 designed to prevent and diagnose delirium early. By digitizing scientifically validated methods such as reorientation, cognitive activation, and screenings, Liv provides hospital staff with the tools to reduce delirium incidence, improve patient outcomes, and lower costs. With a deep understanding of the burden delirium places on patients, families, and healthcare providers, Liv Healthcare focuses on 𝘀𝗲𝗮𝗺𝗹𝗲𝘀𝘀𝗹𝘆 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗻𝗴 𝘁𝗵𝗲𝘀𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀 𝗶𝗻𝘁𝗼 𝗵𝗼𝘀𝗽𝗶𝘁𝗮𝗹 𝘄𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀. Their solution not only enhances patient care but also sets a new standard for addressing cognitive impairments in healthcare. 🚀 Don’t miss the chance to learn how Liv Healthcare is transforming hospital care at the MEDKAP Pitch Event and hear from Samuel L.. 📅 Save the date:  𝟭𝟬.𝟭𝟮.𝟮𝟬𝟮𝟰 🎟️ Contact Vincent Irrling to 𝗿𝗲𝘀𝗲𝗿𝘃𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁! 📄 Become a member at MEDKAP: https://lnkd.in/e23_UV2Q

There is a huge need to align payers, providers (including diagnostic service providers) and patients to simplify and accelerate clinical evidence, guidelines and reimbursement.

In the ever-evolving healthcare landscape, social determinants of health (SDOH) are pivotal factors in influencing patient outcomes. Panalgo's Margaret (Meg) Richards, PhD, MPH, and Andrew Goldstein discuss the core strategies and considerations essential for harnessing SDOH to drive meaningful improvements in patient care. Read the BioPharma Dive article: https://lnkd.in/dFMsa6r7

The integrated diagnostic service by Gateshead and Newcastle is now live. Setting a new standard for collaboration and innovation in healthcare! This milestone represents a significant step in improving patient care by providing faster, more efficient access to diagnostic services across the region. By uniting services under one integrated platform, patients benefit from: ✅ Reduced waiting times for critical diagnostics. ✅ Improved care pathways, ensuring seamless transitions between providers. ✅ Enhanced use of resources, making diagnostics more accessible and efficient. We are proud to contribute to projects that enable interoperability and drive transformational change in healthcare. Initiatives like this showcase the power of collaboration and technology in shaping a more connected, patient-centered NHS. Thanks to Digital Health for the write up! 🔗 Read more about this exciting development: https://lnkd.in/eZq2_iSb #DigitalHealth #HealthcareInnovation #IntegratedCare #NHSPartnerships #PatientCare

𝗖𝗠𝗦 𝗿𝗲𝗹𝗲𝗮𝘀𝗲𝘀 𝗣𝗿𝗼𝗽𝗼𝘀𝗲𝗱 𝗡𝗖𝗗 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗺𝗼 𝗳𝗼𝗿 𝗖𝗮𝗿𝗱𝗶𝗼𝗠𝗘𝗠𝗦 𝗛𝗙 𝗦𝘆𝘀𝘁𝗲𝗺 (𝗜𝗺𝗽𝗹𝗮𝗻𝘁𝗲𝗱 𝗣𝘂𝗹𝗺𝗼𝗻𝗮𝗿𝘆 𝗔𝗿𝘁𝗲𝗿𝘆 𝗣𝗿𝗲𝘀𝘀𝘂𝗿𝗲 𝗦𝗲𝗻𝘀𝗼𝗿 𝗳𝗼𝗿 𝗛𝗲𝗮𝗿𝘁 𝗙𝗮𝗶𝗹𝘂𝗿𝗲 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁) Input from physicians, patients and health advocates are a critical piece of how CMS evaluates reimbursement for therapy advancements used to combat some of society’s most complex medical conditions. We continue to be encouraged by the CMS evaluation of our CardioMEMS HF System as they consider a national coverage determination, and are grateful for the people who have provided input to this point. Increasing access to health innovation is important, and we’re appreciative of CMS assessing CardioMEMS as part of their national coverage determination process.